Presentations
| PRESENTATION & TIMING |
PRESENTERS |
|---|---|
| MORNING & PROGRAM OVERVIEW SESSIONS | |
| 00:04:20 – 00:19:00 | Watch: ASPR WELCOME! – Dr. Robert Kadlec, M.D., MTM&H, M.S.: Assistant Secretary for Preparedness and Response |
| 00:19:00 – 00:37:15 | Watch: HIGHLIGHTED GOVERNMENT PARTNER – Mr. Douglas Bryce, Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) |
| 00:37:15 – 00:50:36 | Watch: INDUSTRY PARTNER –Evan Loh, M.D.: Chief Executive Office Paratek Pharmaceuticals |
| 00:50:36 – 00:58:07 | Watch: HIGHLIGHTED SPEAKER – Mr. Adam Boehler, MBA: Chief Executive Officer of the new U.S. International Development Finance Corporation (DFC) |
| 00:58:07 – 01:11:38 | Watch: HIGHLIGHTED SPEAKER – Michelle McMurry-Heath, M.D., PH.D: President and Chief Executive Office of Biotechnology Innovation Organization (BIO) |
| 01:11:38 – 01:26:25 | Watch: BARDA DIRECTOR’S UPDATE – Dr. Gary Disbrow: Acting Director, Biomedical Advanced Research and Development Authority (BARDA) |
| 01:26:25 – 01:35:59 | Division of Influenza and Emerging Infectious Diseases (IEID) Dr. Robert Johnson, Director |
| 01:35:35 – 01:40:38 | Division of Detection, Diagnostics, & Devices Infrastructure (DDDI) Mr. Rodney Wallace, Director |
| 01:40:38 – 01:49:00 | Division of Research, Innovation, and Ventures (DRIVe) Dr. Sandeep Patel, Director |
| 01:49:00 – 01:57:22 | Division of Contract Management & Acquisitions (CMA) Mr. Enrique Mañán, Acting Direorctor |
| 01:57:22 – 02:08:29 | Division of Chemical, Biological, Radiological and Nuclear Medical Countermeasures (CBRN) Dr. Christopher Houchens, Director |
| 02:10:46 - 02:19:36 pm | Quickfire Challenge Winner |
| 02:19:36 - 02:19:36 pm | BARDA #MakingCountermeasures |
| VIDEO PRESENTATION | BREAKOUT SESSIONS |
| Session 1 Track 1: CBRN Vaccine Programs: Vaccines - Lindsay Parish, PhD; Antivirals & Antitoxins - David Boucher, PhD; Antibacterials - Brian Tse, PhD. | |
| Session 1 Track 2: Division of Clinical Development Overview - Robert Walker; Clinical Operations Branch - Elizabeth Formentini; Biostatistics Branch - James Zhou; Clinical Operations Branch - Marcy Beth Grace | |
| Session 1 Track 3: Blue Knight Panel - Sparking Innovation to Improve the Nation's Response to 21st Century Health Security Threats: Moderator - Ashley Cecere | |
| Session 1 Track 4: Pharmaceutical Countermeasure Infrastructure: Collaborating with our Manufacturing Partners - Arlene Joyner; The National Biopharmaceutical Manufacturing Partnership (BioMaP) - Tim Belski | |
| Session 2 Track 1: Division of Nonclinical Development Overview - April Brys & Claiborne Hughes & James Little; SARS-CoV-2 Response Planning - James Little; SARS-CoV-2 Model Development and Utilization - Allison Totura; SARS-CoV-2 Assay Development - Ashley Smith; BARDA Nonclinical DevelopmentLooking Forward - Claiborne Hughes | |
| Session 2 Track 2: Thermal Burn Medical Countermeasure Program - Janelle Hurwitz; Reimagining Community Preparedness for Mass Casualty Chemical Incidents - William Coley; Radiological & Nuclear Countermeasures Program - John Esker | |
| Session 2 Track 3: Investing in the Future of Health Security Division of Research Innovation & Ventures (DRIVe) - Sandeep Patel | |
| Session 2 Track 4: Contract Management & Acquisitions: Medicalcountermeasures Support Services (MCM-S) - Jeff Schmidt; DRIVe Acquisitions Team - Matt Clay; Station Support & Administrative Contracting (SSAC) - Roseary Hill; Medical Countermeasures Development (MCM-D) - James Harris | |
| Session 3 Track 1: Influenza and Emerging Infectious Diseases: Vaccines - Armen Donabedian; Therapeutics - Kimberly Armstrong; Pandemic Influenza Vaccine Stockpile - Jonathan Seals; | |
| Session 3 Track 2: Regulatory & Quality Affairs - Nina El-Badry; Emergency Use Authorizations (EUAs) - Susan Hollingsworth; JPEO-CBRND - COL Ryan Eckmeier | |
| Session 3 Track 3: CARB-X and Drive Accelerator Networks Wrap Around Services to Prepare for Competitive Funding Engagements - Cameron Bess and Justin Yang | |
| Session 3 Track 4: Detection, Diagnostics, & Devices Infrastructure (DDDI) Division - Rodney Wallace; COVID-19 Timeline & Contracting Approach - John Lee; COVID-19 Dx Manufacturing Capacity Expansion - Charles Daitch; Diagnostics & Medical Devices (The Other Countermeasures); Keys to a Successful White Paper - Paul Eder; EZ-BAA & BAA Solicitation Updates - Jordan Smith | |
| LIGHTNING TALKS - SESSION 1: VACCINES/THERAPEUTICS | |
| 00:00:00 – 00:06:27 | Watch: Adaptive Biotechnologies - Understanding Immunity to SARS-CoV-2: The T Cell Side of the Equation |
| 00:06:28 - 00:10:07 | Watch: Instanosis Inc. - Ultransensitive SARS-CoV-2 Antigen Detection Using Microbubbling |
| 00:10:08 – 00:15:42 | Watch: MeMed - MeMed BV™/Key™: Responding Today, Preparing for Tomorrow. A Host-Protein Test for Combatting Antimicrobial Resistance Plus Biomarkers to Aid in Outbreak Management |
| 00:15:43 – 00:21:13 | Watch: The University of Kansas - Development of a Handheld Radiation Bio-Dosimeter for Point-of-Care Use |
| 00:21:14 – 00:26:32 | Watch: PhenoMx - Multi-Parametric Quantitative Whole-Body Assessment of COVID-19 Infected Individuals for Risk of Chronic Long-Term Conditions |
| 00:26:33 – 00:31:36 | Watch: Promethean LifeSciences - GammaGraft for Burn and Wound Medical Countermeasures Stockpiling |
| 00:31:37 – 00:35:58 | Watch: PharmaJet - Needle-free Delivery of Pandemic Vaccines |
| 00:35:59 – 00:41:38 | Watch: Vir Biotechnology, Inc - Immunological Tools for Pandemic Preparedness |
| 00:41:39 – 00:47:37 | Watch: Autonomous Therapeutics, Inc. - Non-Vaccine, Pan-Genus Prophylactics to Prevent COVID-19 and any Future Beta-Coronavirus Pandemic |
| 00:47:38 – 00:53:56 | Watch: Abimmune Biopharma Inc. - Respiviridin: A Universal Prophylactic & Therapeutic Candidate against Covid-19 and other Respiratory Viruses |
| LIGHTNING TALKS - SESSION 2: DEVICES/DIAGNOSTICS | |
| 00:00:00 – 00:05:49 | Watch: Biomed Industries, Inc. - What does Covid-19 Virus do to the Brain? |
| 00:05:50 – 00:11:42 | Watch: Advanced Innovative Partners/Bio-Nucleonics - Treatment of COVID-19 Virus |
| 00:11:43 – 00:17:28 | Watch: HDT Bio Corp. - Development of RNA-based PAMP Plus LION as a Novel Antiviral Therapy to Limit COVID-19 |
| 00:17:29 – 00:23:18 | Watch: KAER Biotherapeutics Corporation - Therapeutic Surfactant and Biologics Aerosols for the Treatment of Hypoxemia and Respiratory Distress |
| 00:23:19 – 00:28:48 | Watch: Zim Biosciences Inc. - A Technology for the Amelioration of Thermal and/or Chemical Insults to Lung Tissue |
| 00:28:49 – 00:33:50 | Watch: VitriVax - Thermostable, Single-Shot Vaccine Formulation Platform |
| 00:33:51 – 00:39:43 | Watch: FluGen Inc. - M2SR Seroconversion Against H3N2 Proximate & Distant Drift |
| 00:39:44 – 00:45:12 | Watch: Virica Biotech Inc. - Viral Sensitizers: Accelerating Vaccine Production and Pandemic Response |
| 00:45:13 – 00:51:05 | Watch: Codex DNA - Establishing a Global Network of Vaccine Printers |
| 00:51:06 – 00:57:03 | Watch: Persephone Biosciences - Arming the Immune System Using Gut Microbiome Therapeutics to Prevent and Fight SARS-CoV-2 |
